Detection and characterization of liver lesions using gadoxetic acid as a tissue-specific contrast agent

References

• LivraghiTMeloniFMorabitoAVettoriCMultimodal image-guided tailored therapy of early and intermediate hepatocellular carcinoma: long-term survival in the experience of a single radiologic referral centerLiver Transpl2004102 Suppl 1S98S10614762848
   PubMedGoogle Scholar
• ThomasMBAbbruzzeseJLOpportunities for targeted therapies in hepatocellular carcinomaJ Clin Oncol200523318093810816258107
   PubMed Web of Science ®Google Scholar
• FargionSFracanzaniALValentiLTreatment choices for people infected with HCVJ Antimicrob Chemother200453570871215073158
   PubMed Web of Science ®Google Scholar
• BrunoSCrosignaniAMaisonneuvePRossiSSiliniEMondelliMUHepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort studyHepatology20074651350135617680653
   PubMed Web of Science ®Google Scholar
• El-SeragHBHepatocellular carcinoma: an epidemiologic viewJ Clin Gastroenterol2002355 Suppl 2S72S7812394209
   PubMed Web of Science ®Google Scholar
• El-SeragHBHepatocellular carcinoma and hepatitis C in the United StatesHepatology2002365 Suppl 1S74S8312407579
   PubMed Web of Science ®Google Scholar
• El-SeragHBHepatocellular carcinoma: recent trends in the United StatesGastroenterology20041275 Suppl 1S27S3415508094
   PubMed Web of Science ®Google Scholar
• SzymanskaKChenJGCuiYTP53 R249S mutations, exposure to aflatoxin, and occurrence of hepatocellular carcinoma in a cohort of chronic hepatitis B virus carriers from Qidong, ChinaCancer Epidemiol Biomarkers Prev20091851638164319366907
   PubMed Web of Science ®Google Scholar
• http://www.usclivercancer.org/
   Google Scholar
• VivarelliMBellusciRCucchettiALow recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression?Transplantation200274121746175112499891
   PubMed Web of Science ®Google Scholar
• El-SeragHBMarreroJARudolphLReddyKRDiagnosis and treatment of hepatocellular carcinomaGastroenterology200813461752176318471552
   PubMed Web of Science ®Google Scholar
• El-SeragHBRudolphKLHepatocellular carcinoma: epidemiology and molecular carcinogenesisGastroenterology200713272557257617570226
   PubMed Web of Science ®Google Scholar
• http://search.medscape.com/emedicine-search?queryText=liver%20tumor
   Google Scholar
• ShenYHFanJWuZQFocal nodular hyperplasia of the liver in 86 patientsHepatobiliary Pancreat Dis Int200761525717287167
   PubMed Web of Science ®Google Scholar
• FariaSCIyerRBRashidAWhitmanGJHepatic adenomaAJR Am J Roentgenol20041826152015149999
   PubMed Web of Science ®Google Scholar
• KasperHUDrebberUDriesVDienesHP[Liver metastases: incidence and histogenesis]Z Gastroenterol200543101149115716220456
   PubMed Web of Science ®Google Scholar
• KanematsuMKondoHGoshimaSImaging liver metastases: review and updateEur J Radiol200658221722816406434
   PubMed Web of Science ®Google Scholar
• WeinmannHJSchuhmann-GiampieriGSchmitt-WillichHVoglerHFrenzelTGriesHA new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRIMagn Reson Med1991222233237discussion 242.1812351
   PubMed Web of Science ®Google Scholar
• CavagnaFDapraMMaggioniFde HaenCFelderEGd-BOPTA/Dimeg: experimental disease imagingMagn Reson Med1991222329333discussion 43–46.1812366
   PubMed Web of Science ®Google Scholar
• YoungSWBradleyBMullerHHRubinDLDetection of hepatic malignancies using Mn-DPDP (manganese dipyridoxal diphosphate) hepatobiliary MRI contrast agentMagn Reson Imaging1990832672762114511
   PubMed Web of Science ®Google Scholar
• RungeVMPels RijckenTHDavidoffAWellsJWStarkDDContrast-enhanced MR imaging of the liverJ Magn Reson Imaging1994432812898061423
   PubMed Web of Science ®Google Scholar
• MitchellDGHepatobiliary contrast material: a magic bullet for sensitivity and specificity?Radiology1993188121228511300
   PubMed Web of Science ®Google Scholar
• PascoloLCupelliFAnelliPLMolecular mechanisms for the hepatic uptake of magnetic resonance imaging contrast agentsBiochem Biophys Res Commun1999257374675210208854
   PubMed Web of Science ®Google Scholar
• Schuhmann-GiampieriGFrenzelTSchmitt-WillichHPharmacokinetics in rats, dogs and monkeys of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imagingArzneimittelforschung19934389279318216456
   PubMed Web of Science ®Google Scholar
• Schuhmann-GiampieriGSchmitt-WillichHFrenzelTSchitt-WillichHBiliary excretion and pharmacokinetics of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging in the ratJ Pharm Sci19938287998038377117
   PubMed Web of Science ®Google Scholar
• Schuhmann-GiampieriGSchmitt-WillichHPressWRNegishiCWeinmannHJSpeckUPreclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary systemRadiology1992183159641549695
   PubMed Web of Science ®Google Scholar
• HammBStaksTMuhlerAPhase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imagingRadiology199519537857927754011
   PubMed Web of Science ®Google Scholar
• MuhlerAClementOSaeedMGadolinium-ethoxybenzyl-DTPA, a new liver-directed magnetic resonance contrast agent. Absence of acute hepatotoxic, cardiovascular, or immunogenic effectsInvest Radiol199328126328425849
   PubMed Web of Science ®Google Scholar
• MuhlerAClementOVexlerVBerthezeneYRosenauWBraschRCHepatobiliary enhancement with Gd-EOB-DTPA: comparison of spin-echo and STIR imaging for detection of experimental liver metastasesRadiology199218412072131609081
   PubMed Web of Science ®Google Scholar
• MuhlerAHeinzelmannIWeinmannHJElimination of gadolinium-ethoxybenzyl-DTPA in a rat model of severely impaired liver and kidney excretory function. An experimental study in ratsInvest Radiol199429221368169100
   PubMed Web of Science ®Google Scholar
• MuhlerAWeinmannHJBiodistribution and excretion of 153Gd-labeled gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid following repeated intravenous administration to ratsAcad Radiol1995243133189419568
   PubMed Web of Science ®Google Scholar
• Schmitt-WillichHBrehmMEwersCLSynthesis and physicochemical characterization of a new gadolinium chelate: the liver-specific magnetic resonance imaging contrast agent Gd-EOB-DTPAInorg Chem19993861134114411670895
   PubMed Web of Science ®Google Scholar
• Schuhmann-GiampieriGNonlinear pharmacokinetic modeling of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imagingArzneimittelforschung1993439102010248240452
   PubMed Web of Science ®Google Scholar
• Schuhmann-GiampieriGLiver contrast media for magnetic resonance imaging. Interrelations between pharmacokinetics and imagingInvest Radiol19932887537618376008
   PubMed Web of Science ®Google Scholar
• Schuhmann-GiampieriGMahlerMRollGMaibauerRSchmitzSPharmacokinetics of the liver-specific contrast agent Gd-EOB-DTPA in relation to contrast-enhanced liver imaging in humansJ Clin Pharmacol19973775875969243351
   PubMed Web of Science ®Google Scholar
• BollowMTaupitzMHammBStaksTWolfKJWeinmannHJGadolinium-ethoxybenzyl-DTPA as a hepatobiliary contrast agent for use in MR cholangiography: results of an in vivo phase-I clinical evaluationEur Radiol1997711261329000414
   PubMed Web of Science ®Google Scholar
• ReimerPRummenyEJShamsiKPhase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequenceRadiology199619911771838633143
   PubMed Web of Science ®Google Scholar
• HammerstinglRZangosSSchwarzWContrast-enhanced MRI of focal liver tumors using a hepatobiliary MR contrast agent: detection and differential diagnosis using Gd-EOB-DTPA-enhanced versus Gd-DTPA-enhanced MRI in the same patientAcad Radiol20029Suppl 1S119S12012019845
   PubMed Web of Science ®Google Scholar
• ZangosSHammerstinglRMackMGRenal enhancement and excretion of the hepatobiliary contrast agent Gd-EOB-DTPARofo2001173111034104011704914
   PubMedGoogle Scholar
• VoglTJKummelSHammerstinglRLiver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPARadiology1996200159678657946
   PubMed Web of Science ®Google Scholar
• HammerstinglRHuppertzABreuerJDiagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesionsEur Radiol200818345746718058107
   PubMed Web of Science ®Google Scholar
• HuppertzABalzerTBlakeboroughAImproved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findingsRadiology2004230126627514695400
   PubMed Web of Science ®Google Scholar
• BluemkeDASahaniDAmendolaMEfficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III studyRadiology20052371899816126918
   PubMed Web of Science ®Google Scholar
• http://www.medicalnewstoday.com/articles/114315.php
   Google Scholar
• http://www.clinicaltrial.gov/ct2/show/NCT00924248
   Google Scholar
• http://clinicaltrials.gov/ct2/show/NCT00526188
   Google Scholar
• BreuerJStudy of the Safety of Gd-EOB-DTPA and the Effect of Hepatic and Renal Impairment on the Pharmacokinetics (PK) and the Pharmacodynamics (PD) of Gd-EOB-DTPA after a Single Intravenous Dose in Volunteer Patients, BBerlin, GermanySchering AG2003
   Google Scholar
• ZechCJGrazioliLJonasEHealth-economic evaluation of three imaging strategies in patients with suspected colorectal liver metastases: Gd-EOB-DTPA-enhanced MRI vs. extracellular contrast media-enhanced MRI and 3-phase MDCT in Germany, Italy and SwedenEur Radiol200919Suppl 3S753S76319484243
   PubMed Web of Science ®Google Scholar
• ZechCJHerrmannKAReiserMFSchoenbergSOMR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPAMagn Reson Med Sci200761435217510541
   PubMedGoogle Scholar
• KuhnJPHegenscheidKSiegmundWFroehlichCPHostenNPulsRNormal dynamic MRI enhancement patterns of the upper abdominal organs: gadoxetic acid compared with gadobutrolAJR Am J Roentgenol200919351318132319843748
   PubMed Web of Science ®Google Scholar
• KimYKKwakHSKimCSHanYMDetection and characterization of focal hepatic tumors: a comparison of T2-weighted MR images before and after the administration of gadoxectic acidJ Magn Reson Imaging200930243744319629973
   PubMed Web of Science ®Google Scholar
• ReimerPRummenyEJDaldrupHEEnhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imagingEur Radiol1997722752809038130
   PubMed Web of Science ®Google Scholar
• HuppertzAHaraidaSKrausAEnhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT–initial observationsRadiology2005234246847815591431
   PubMed Web of Science ®Google Scholar
• SaitoKKotakeFItoNGd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phaseMagn Reson Med Sci2005411916127248
   PubMedGoogle Scholar
• ShimofusaRUedaTKishimotoTMagnetic resonance imaging of hepatocellular carcinoma: a pictorial review of novel insights into pathophysiological features revealed by magnetic resonance imagingJ Hepatobiliary Pancreat SurgEpub 2009 Oct 7.
   Google Scholar
• Ba-SsalamahAFakhraiNMatzekWKMagnetic resonance imaging of liver malignanciesTop Magn Reson Imaging200718644545518303402
   PubMedGoogle Scholar
• FujitaMYamamotoRTakahashiMParadoxic uptake of Gd-EOB-DTPA by hepatocellular carcinoma in mice: quantitative image analysisJ Magn Reson Imaging1997747687709243401
   PubMed Web of Science ®Google Scholar
• JungGBreuerJPollLWImaging characteristics of hepatocellular carcinoma using the hepatobiliary contrast agent Gd-EOB-DTPAActa Radiol2006471152316498928
   PubMed Web of Science ®Google Scholar
• SunHYLeeJMShinCIGadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imagingInvest Radiol20104529610320057319
   PubMed Web of Science ®Google Scholar
• NaritaMHatanoEArizonoSExpression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinomaJ Gastroenterol200944779379819404564
   PubMed Web of Science ®Google Scholar
• FrericksBBLoddenkemperCHuppertzAQualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPAAJR Am J Roentgenol200919341053106019770329
   PubMed Web of Science ®Google Scholar
• KimSHKimSHLeeJGadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinomaAJR Am J Roentgenol200919261675168119457834
   PubMed Web of Science ®Google Scholar
• Ba-SsalamahAUffmannMSainiSBastatiNHeroldCSchimaWClinical value of MRI liver-specific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal liver lesionsEur Radiol200919234235718810454
   PubMed Web of Science ®Google Scholar
• BrodyJMSchaferLTungGABreuerJShamsiKConspicuity of liver hemangiomas: short tau inversion recovery, T1, and T2 imaging with gadolinium ethoxybenzyl diethylenetriaminepentaacetic acidJ Magn Reson Imaging200521439139715778951
   PubMed Web of Science ®Google Scholar
• ZechCJGrazioliLBreuerJReiserMFSchoenbergSODiagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trialInvest Radiol200843750451118580333
   PubMed Web of Science ®Google Scholar
• KaclGMHagspielKDMarincekBFocal nodular hyperplasia of the liver: serial MRI with Gd-DOTA, superparamagnetic iron oxide, and Gd-EOB-DTPAAbdom Imaging19972232642679107647
   PubMedGoogle Scholar
• GiovanoliOHeimMTerraccianoLBongartzGLedermannHPMRI of hepatic adenomatosis: initial observations with gadoxetic acid contrast agent in three patientsAJR Am J Roentgenol20081905W290W29318430814
   PubMed Web of Science ®Google Scholar
• KuwatsuruR[MR imaging of liver metastasis using Gd-EOB-DTPA]Gan To Kagaku Ryoho20093681234124119692760
   PubMedGoogle Scholar
• ShimadaMHayashiSSenooA[Dynamic MR hepatocholangiography with the SIP Fast GRE (saturation inversion projection fast gradient echo) method]Nippon Igaku Hoshasen Gakkai Zasshi199757116816839364857
   PubMedGoogle Scholar
• ShimizuJDonoKGotohMEvaluation of regional liver function by gadolinium-EOB-DTPA-enhanced MR imagingDig Dis Sci19994471330133710489914
   PubMed Web of Science ®Google Scholar
• ShuterBWangSCRocheJBriggsGPopeJMRelaxivity of Gd-EOB-DTPA in the normal and biliary obstructed guinea pigJ Magn Reson Imaging1998848538619702887
   PubMed Web of Science ®Google Scholar
• TschirchFTStruweAPetrowskyHKakalesIMarincekBWeishauptDContrast-enhanced MR cholangiography with Gd-EOB-DTPA in patients with liver cirrhosis: visualization of the biliary ducts in comparison with patients with normal liver parenchymaEur Radiol20081881577158618369632
   PubMed Web of Science ®Google Scholar
• CarlosRCBranamJDDongQHussainHKFrancisIRBiliary imaging with Gd-EOB-DTPA: is a 20-minute delay sufficient?Acad Radiol20029111322132512449364
   PubMed Web of Science ®Google Scholar
• CarlosRCHussainHKSongJHFrancisIRGadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid as an intrabiliary contrast agent: preliminary assessmentAJR Am J Roentgenol20021791879212076911
   PubMed Web of Science ®Google Scholar
• FilipponeABlakeboroughABreuerJEnhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumineJ Magn Reson Imaging201031235636420099349
   PubMed Web of Science ®Google Scholar
• IchikawaTSaitoKYoshiokaNDetection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver diseaseInvest Radiol201045313314120098330
   PubMed Web of Science ®Google Scholar
• KimYKLeeYHKwakHSKimCSHanYMDetection of liver metastases: gadoxetic acid-enhanced three-dimensional MR imaging versus ferucarbotran-enhanced MR imagingEur J Radiol200873113113618996659
   PubMed Web of Science ®Google Scholar
• HalavaaraJBreuerJAyusoCLiver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT – a multicenter trialJ Comput Assist Tomogr200630334535416778605
   PubMed Web of Science ®Google Scholar